A Phase Two Randomised Controlled Trial of Belimumab in Kidney Transplant Recipients Demonstrates Comparable Safety, a Reduction in De Novo Antibody Production and an Increase in Regulatory B Cells.
Ontology highlight
ABSTRACT: There is an urgent unmet need in solid organ transplantation for immunotherapeutic strategies that target B cells and plasma cells, ideally without increasing infectious complications. We conducted a phase 2 double-blind randomised placebo-controlled trial to assess the safety and potential efficacy of an anti-BLyS antibody, belimumab, in addition to standard of care immunosuppression post-kidney transplantation.
ORGANISM(S): Homo sapiens
SUBMITTER: Paul Wilson
PROVIDER: E-MTAB-5906 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA